BACKGROUND AND PURPOSE: The role of subthalamic nucleus deep brain stimulation ( @entity9221 DBS) in the treatment of @entity191 ( @entity191 ) is well established. The authors present a group of @entity1 diagnosed with @entity191 who were treated with @entity9221 DBS. MATERIAL AND METHODS: Between 2008 and 2009, 32 female and 34 male @entity1 with @entity191 were treated with @entity9221 DBS. Mean age at implantation was 57    12 years. @entity191 lasted from 6 to 21 years (mean 10 years). @entity1 were qualified for the surgery according to the @entity191 criteria. The @entity9221 was identified with direct and indirect methods. Macrostimulation and microrecording for @entity9221 identification were used in all cases. A unilateral @entity9221 DBS system was implanted in two cases and bilateral implantation was performed among rest of the group. Outcome was assessed six months after implantation. Results : The mean reduction of UPDRS III score among 51 @entity1 who underwent follow-up was 45% (5-89%). Reduction of levodopa consumption varied from 15 to 100%. @entity281 forced the authors to remove the DBS system in one case four months after implantation. @entity272 above the internal pulse generator was noted in four cases. CONCLUSIONS: Cardinal symptoms of @entity191 can be safely and effectively treated with @entity9221 DBS in selected group of @entity1 .

Subthalamic deep brain stimulation for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity9221 :: ('1917', 'Gene') :: ['STN'] @entity191 :: ('MESH:D010300', 'Disease') :: ['Parkinson disease', 'CAPSIT-PD', "Parkinson's disease", 'PD'] @entity281 :: ('MESH:D007239', 'Disease') :: ['Infection'] @entity272 :: ('MESH:D012871', 'Disease') :: ['Skin erosion']
@entity191 :: (MESH:D010300,Disease) :: ['Parkinson disease']
